The Effectiveness of Two Distinct Ventilation Strategies Escalating Positive End Expiratory Pressure (PEEP) and Lung Recruitment Maneuvers in Improving Oxygenation

March 6, 2025 updated by: Ain Shams University

Comparative Study of Escalating PEEP (Positive End Expiratory Pressure) Vs. Lung Recruitment by Sustained Inflation Strategies for Managing Hypoxemia in COPD Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)

This study evaluates and compares the effectiveness of two distinct ventilation strategies-escalating PEEP and lung recruitment maneuvers-in improving oxygenation (i.e., managing hypoxemia) in COPD patients undergoing VATS.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

A) Preoperative settings :

  • Written informed consent will be obtained from all participants prior to the study.
  • Pre-operative optimisation of patients include cessation of smoking, improvement of pulmonary functions using bronchodilators and steroids, pre-operative chest physiotherapy and training of patient with lung expansion manuoevers. Reversible components of COPD such as bronchospasm, infections, and pulmonary oedema should be actively looked for and treated aggressively 9.
  • Detection of severity of COPD by using The Global Initiative for Chronic Obstructive Lung Disease (GOLD) system categorizes airflow limitation into stages. In patients with FEV₁/FVC <0.7:

    • GOLD 1 - mild: FEV₁ ≥80% predicted
    • GOLD 2 - moderate: 50% ≤ FEV₁ <80% predicted
    • GOLD 3 - severe: 30% ≤ FEV₁ <50% predicted
    • GOLD 4 - very severe: FEV₁ <30% predicted 10.
  • Preoperative assessment evaluates lung mechanics, parenchymal function, and cardiopulmonary reserve to determine a patient's suitability for surgery. Lung mechanics, including forced expiratory volume in 1 second (FEV1), maximum voluntary ventilation, forced vital capacity, and residual volume/total lung capacity (RV/TLC) ratio, provide insights into respiratory function. An FEV1 greater than 60% indicates potential tolerance for anatomic lobe resection. An FEV1 of less than 30% suggests postoperative ventilator or supplemental oxygen dependence. In FEV1s less than 60%, a ventilation-perfusion scan (VQ scan) may calculate a postoperative FEV1, with values above 35% (and up to 40%), suggesting adequate postoperative pulmonary reserve. DLCO, measuring gas diffusion, ideally exceeds 40% for surgery. Cardiopulmonary exercise testing assesses overall reserve, with a maximum rate of oxygen (O2) your body can use during exercise (VO2) greater than 10 mL/min/kg, indicating suitability for surgery 2.
  • Preoperative assessment for VATS also involves evaluating blood counts for indications of polycythemia or infection. Chest x-rays and CT scans provide anatomical details for surgical planning. Arterial blood gases identify patients at risk for postoperative complications; a partial pressure of carbon dioxide (CO2) more than 50 mm Hg or a partial pressure of O2 less than 60 mm Hg indicates vulnerability 2.

B) Intraoperative settings:

Electrocardiogram (ECG), non-invasive blood pressure (NIBP), pulse oximeter (SpO2) will be applied, and baseline readings will be taken before induction.

Anaesthesia will be induced after a period of preoxygenation with 100% oxygen for 2-3 minutes with intravenous injection of fentanyl 2 µg/kg, propofol 2 mg/kg and a muscle relaxant (Atracurium) 0.5 mg/kg after loss of patient consciousness. Lung isolation is achieved using a double-lumen endotracheal tube, Fiberoptic bronchoscopy is typically used to guide and confirm the placement and positioning of the tube 11.

Patients often requires the placement of invasive monitoring devices, such as invasive blood pressure (IBP) lines and central venous lines (CVL).

Anaesthesia will be maintained by 1-2 % of isoflurane in 50% oxygen/air mixture according to oxygen state and 0.1 mg/kg atracurium, ventilation parameters that maintain normocapnia (CO2 between 35- 40 mmHg). Fluids as crystalloids used by a fluid chart for the deficit and maintenance as needed.

The surgery typically begins with the patient positioned in a full lateral decubitus posture tailored to the side of the operation or in a supine position with appropriate support to access the chest.

Ventilatory setting:

Typically, an initial PEEP of 5 cm H₂O is used in all patients,

Group A:

PEEP is typically increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).

Group B:

A sustained inflation:

Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.

C) Postoperative settings:

Follow up patients in recovery room whether transferred to ICU or to Ward, data will be recorded at the following times 1 h, 2 h, 6 h, 12 h, and 24 h. Both groups will be compared to each other according to the following variables:

  • Hypoxemia
  • The Need for mechanical ventilation

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11111
        • Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 20 years and </=60 years.
  • Both sex.
  • Patients American Society of Anesthesiologists Physical Status (ASA) Il to IIl.
  • A written, valid, and informed consent
  • Mild to moderate COPD patients
  • BMI less than 4

Exclusion Criteria:

  • Patient refusal.
  • Pregnancy
  • VATS procedure converted to open thoracotomy
  • Patients have other lung diseases
  • Patients ASA more than lll
  • Patients with cardiac diseases affecting systolic & diastolic functions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group (A): Escalating PEEP
This group will undergo VATS & one hypoxemia started PEEP is typically increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).
Typically, an initial PEEP of 5 cm H₂O, then PEEP is increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).
Active Comparator: Group (B): Lung recruitment by Sustained inflation

A sustained inflation:

Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.

Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of ICU admission
Time Frame: 6 months
The incidence of post-operative patients requiring ICU admission
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of pulmonary complications
Time Frame: 6 months
Intraoperative Hemodynamic instability, hypoxemia & Hypercapnia Post operative Needs of mechanical ventilation. Post operative pulmonary complications.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Ahmed Nagah AL Shaer, Professor, Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2025

Primary Completion (Estimated)

July 27, 2025

Study Completion (Estimated)

July 27, 2025

Study Registration Dates

First Submitted

February 21, 2025

First Submitted That Met QC Criteria

February 21, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 6, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FMASU MS 40/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All dana will be shared once study is completed

IPD Sharing Time Frame

Before 1/2026

IPD Sharing Access Criteria

Free

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Escalating PEEP

Subscribe